Pharmacomicrobiomics: Immunosuppressive Drugs and Microbiome Interactions in Transplantation.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
16 Feb 2024
16 Feb 2024
Historique:
medline:
16
2
2024
pubmed:
16
2
2024
entrez:
16
2
2024
Statut:
aheadofprint
Résumé
The human microbiome is associated with human health and disease. Exogenous compounds, including pharmaceutical products, are also known to be affected by the microbiome, and this discovery has led to the field of pharmacomicobiomics. The microbiome can also alter drug pharmacokinetics and pharmacodynamics, possibly resulting in side effects, toxicities, and unanticipated disease response. Microbiome-mediated effects are referred to as drug-microbiome interactions (DMI). Rapid advances in the field of pharmacomicrobiomics have been driven by the availability of efficient bacterial genome sequencing methods and new computational and bioinformatics tools. The success of fecal microbiota transplantation for recurrent Clostridioides difficile has fueled enthusiasm and research in the field. This review focuses on the pharmacomicrobiome in transplantation. Alterations in the microbiome in transplant recipients are well documented, largely because of prophylactic antibiotic use, and the potential for DMI is high. There is evidence that the gut microbiome may alter the pharmacokinetic disposition of tacrolimus and result in microbiome-specific tacrolimus metabolites. The gut microbiome also impacts the enterohepatic recirculation of mycophenolate, resulting in substantial changes in pharmacokinetic disposition and systemic exposure. The mechanisms of these DMI and the specific bacteria or communities of bacteria are under investigation. There are little or no human DMI data for cyclosporine A, corticosteroids, and sirolimus. The available evidence in transplantation is limited and driven by small studies of heterogeneous designs. Larger clinical studies are needed, but the potential for future clinical application of the pharmacomicrobiome in avoiding poor outcomes is high.
Identifiants
pubmed: 38361239
doi: 10.1097/TP.0000000000004926
pii: 00007890-990000000-00663
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Levy M, Kolodziejczyk AA, Thaiss CA, et al. Dysbiosis and the immune system. Nat Rev Immunol. 2017;17:219–232.
Durack J, Lynch SV. The gut microbiome: relationships with disease and opportunities for therapy. J Exp Med. 2019;216:20–40.
Fernandes MR, Aggarwal P, Costa RGF, et al. Targeting the gut microbiota for cancer therapy. Nat Rev Cancer. 2022;22:703–722.
Vijay A, Valdes AM. Role of the gut microbiome in chronic diseases: a narrative review. Eur J Clin Nutr. 2022;76:489–501.
Gibson CM, Childs-Kean LM, Naziruddin Z, et al. The alteration of the gut microbiome by immunosuppressive agents used in solid organ transplantation. Transpl Infect Dis. 2021;23:e13397.
Bhat M, Pasini E, Copeland J, et al. Impact of immunosuppression on the metagenomic composition of the intestinal microbiome: a systems biology approach to post-transplant diabetes. Sci Rep. 2017;7:10277.
Zhang Z, Xu Y, Hu X. Immunosuppressive treatment alters gut microbiota and modified gut microbiota affects immune status. Transplantation. 2017;101:S51.
García-Martínez Y, Borriello M, Capolongo G, et al. The gut microbiota in kidney transplantation: a target for personalized therapy? Biology (Basel). 2023;12:163.
Gabarre P, Loens C, Tamzali Y, et al. Immunosuppressive therapy after solid organ transplantation and the gut microbiota: Bidirectional interactions with clinical consequences. Am J Transplant. 2022;22:1014–1030.
Zhang Z, Liu L, Tang H, et al. Immunosuppressive effect of the gut microbiome altered by high-dose tacrolimus in mice. Am J Transplant. 2018;18:1646–1656.
Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020;69:1510–1519.
Dikeocha IJ, Al-Kabsi AM, Miftahussurur M, et al. Pharmacomicrobiomics: influence of gut microbiota on drug and xenobiotic metabolism. FASEB J. 2022;36:e22350.
Tsunoda SM, Gonzales C, Jarmusch AK, et al. Contribution of the gut microbiome to drug disposition, pharmacokinetic and pharmacodynamic variability. Clin Pharmacokinet. 2021;60:971–984.
Becker HEF, Demers K, Derijks LJJ, et al. Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease. Front Microbiol. 2023;14:1107976.
Brown LC, Bobo WV, Gall CA, et al. Pharmacomicrobiomics of antidepressants in depression: a systematic review. J Pers Med. 2023;13:1086.
Džidić-Krivić A, Kusturica J, Sher EK, et al. Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs. Drug Metab Rev. 2023;55:126–139.
Vemuri R, Shankar EM, Chieppa M, et al. Beyond just bacteria: functional biomes in the gut ecosystem including virome, mycobiome, archaeome and helminths. Microorganisms. 2020;8:483.
Khoruts A, Staley C, Sadowsky MJ. Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology. Nat Rev Gastroenterol Hepatol. 2021;18:67–80.
U.S. Food and Drug Administration. FDA approves first orally administered fecal microbiota product for the prevention of recurrence of Clostridioides difficile infection. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-orally-administered-fecal-microbiota-product-prevention-recurrence-clostridioides. Accessed August 30, 2023.
Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555:623–628.
Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, et al. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019;570:462–467.
Bromberg JS, Fricke WF, Brinkman CC, et al. Microbiota—implications for immunity and transplantation. Nat Rev Nephrol. 2015;11:342–353.
Przybyciński J, Drożdżal S, Wilk A, et al. The effect of the gut microbiota on transplanted kidney function. Int J Mol Sci . 2023;24:1260.
Vich Vila A, Collij V, Sanna S, et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020;11:362.
Heirali A, Moossavi S, Arrieta MC, et al. Principles and terminology for host–microbiome–drug interactions. Open Forum Infect Dis. 2023;10:ofad195.
Annual Data Report of the US Organ Procurement and Transplantation Network (OPTN) and the Scientific Registry of Transplant Recipients (SRTR). Preface. Am J Transplant. 2013;13(Suppl 1):1–7.
Ong SC, Gaston RS. Thirty years of tacrolimus in clinical practice. Transplantation. 2021;105:484–495.
Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404–430.
Oetting WS, Schladt DP, Guan W, et al.; DeKAF Investigators. Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identifies multiple CYP3A5 alleles. Am J Transplant. 2016;16:574–582.
Borra LCP, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010;25:2757–2763.
Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2:374–384.
Schumacher L, Leino AD, Park JM. Tacrolimus intrapatient variability in solid organ transplantation: a multiorgan perspective. Pharmacotherapy. 2021;41:103–118.
Gaynor JJ, Ciancio G, Guerra G, et al. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. Transpl Int. 2016;29:216–226.
Davis S, Gralla J, Klem P, et al. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018;18:907–915.
Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481–508.
Anghel D, Tanasescu R, Campeanu A, et al. Neurotoxicity of immunosuppressive therapies in organ transplantation. Maedica. 2013;8:170–175.
Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17:1304–1309.
Bulatova N, Yousef AM, Al-Khayyat G, et al. Adverse effects of tacrolimus in renal transplant patients from living donors. Curr Drug Saf. 2011;6:3–11.
Roberts MB, Fishman JA. Immunosuppressive agents and infectious risk in transplantation: managing the “net state of immunosuppression.” Clin Infect Dis. 2021;73:e1302–e1317.
Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007;22:328–335.
Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos. 1995;23:1315–1324.
de Jonge H, de Loor H, Verbeke K, et al. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther. 2012;92:366–375.
Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268:6077–6080.
Möller A, Iwasaki K, Kawamura A, et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos. 1999;27:633–636.
Brunet M, Pastor-Anglada M. Insights into the pharmacogenetics of tacrolimus pharmacokinetics and pharmacodynamics. Pharmaceutics. 2022;14:1755.
Degraeve AL, Moudio S, Haufroid V, et al. Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. Expert Opin Drug Metab Toxicol. 2020;16:769–782.
Kagaya H, Niioka T, Saito M, et al. Prediction of tacrolimus exposure by CYP3A5 genotype and exposure of co-administered everolimus in Japanese renal transplant recipients. Int J Mol Sci . 2018;19:882.
Oetting WS, Wu B, Schladt DP, et al. Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients. Pharmacogenomics J. 2018;18:501–505.
Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015;98:19–24.
Soda M, Fujitani M, Michiuchi R, et al. Association between tacrolimus pharmacokinetics and cytochrome P450 3A5 and multidrug resistance protein 1 exon 21 polymorphisms. Transplant Proc. 2017;49:1492–1498.
Rong G, Jing L, Deng-Qing L, et al. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. Transplant Proc. 2010;42:3455–3458.
Vannaprasaht S, Reungjui S, Supanya D, et al. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation. Clin Ther. 2013;35:1762–1769.
Yang TH, Chen YK, Xue F, et al. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation. Int J Clin Pract Suppl. 2015;69:53–62.
Miyata Y, Akamatsu N, Sugawara Y, et al. Pharmacokinetics of a once-daily dose of tacrolimus early after liver transplantation: with special reference to CYP3A5 and ABCB1 single nucleotide polymorphisms. Ann Transplant. 2016;21:491–499.
Shi Y, Li Y, Tang J, et al. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Gene. 2013;512:226–231.
Lee JR, Muthukumar T, Dadhania D, et al. Gut microbiota and tacrolimus dosing in kidney transplantation. PLoS One. 2015;10:e0122399.
Jennings DL, Bohn B, Zuver A, et al. Gut microbial diversity, inflammation, and oxidative stress are associated with tacrolimus dosing requirements early after heart transplantation. PLoS One. 2020;15:e0233646.
Kim JE, Kim HE, Cho H, et al. Gut Faecalibacterium may improve impaired tacrolimus metabolism in kidney transplant recipients with cytochrome polymorphism. Korean J Transplant. 2020;34:S33–S33.
Dela Cruz M, Lin H, Adler E, et al. The gut microbiome and tacrolimus dosing in the peri-heart transplant period. J Heart Lung Transplant. 2022;41:S122.
Lee SK, Jhun J, Lee SY, et al. A decrease in functional microbiomes represented as Faecalibacterium affects immune homeostasis in long-term stable liver transplant patients. Gut Microbes. 2022;14:2102885. https://www.tandfonline.com/doi/pdf/10.1080/19490976.2022.2102885?needAccess=true.
Ling Q, Han Y, Ma Y, et al. Alterations in the gut microbiome in liver recipients with post-transplant diabetes mellitus. Engineering. 2023. doi: 10.1016/j.eng.2023.09.006.
doi: 10.1016/j.eng.2023.09.006
Degraeve AL, Bindels LB, Haufroid V, et al. Tacrolimus pharmacokinetics is associated with gut microbiota diversity in kidney transplant patients: results from a pilot cross-sectional study. Clin Pharmacol Ther. 2024;115:104–115.
Saqr A, Carlson B, Staley C, et al. Reduced enterohepatic recirculation of mycophenolate and lower blood concentrations are associated with the stool bacterial microbiome after hematopoietic cell transplantation. Transplant Cell Ther. 2022;28:372.e1–372.e9.
Guo Y, Crnkovic CM, Won KJ, et al. Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites. Drug Metab Dispos. 2019;47:194–202.
Guo Y, Lee H, Edusei E, et al. Blood profiles of gut bacterial tacrolimus metabolite in kidney transplant recipients. Transplant Direct. 2020;6:e601.
Qian L, Ouyang H, Gordils-Valentin L, et al. Identification of gut bacterial enzymes for keto-reductive metabolism of xenobiotics. ACS Chem Biol. 2022;17:1665–1671.
Firdaous I, Verbeeck RK, Hassoun A, et al. Excretion of tacrolimus glucuronides in human bile. Eur J Drug Metab Pharmacokinet. 1997;22:217–221.
Tron C, Rayar M, Petitcollin A, et al. A high performance liquid chromatography tandem mass spectrometry for the quantification of tacrolimus in human bile in liver transplant recipients. J Chromatogr A. 2016;1475:55–63.
Strassburg CP, Barut A, Obermayer-Straub P, et al. Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7. J Hepatol. 2001;34:865–872.
Collins SL, Patterson AD. The gut microbiome: an orchestrator of xenobiotic metabolism. Acta Pharm Sin B. 2020;10:19–32.
Pollet RM, D’Agostino EH, Walton WG, et al. An atlas of β-glucuronidases in the human intestinal microbiome. Structure. 2017;25:967–977.e5.
Tron C, Petitcollin A, Verdier MC, et al. Tacrolimus: does direct glucuronidation matter? An analytical and pharmacological perspective. Pharmacol Res. 2017;124:164–166.
Dempsey JL, Cui JY. Microbiome is a functional modifier of P450 drug metabolism. Curr Pharmacol reports. 2019;5:481–490.
Togao M, Kurakawa T, Tajima S, et al. Human gut microbiota influences drug-metabolizing enzyme hepatic Cyp3a: a human flora-associated mice study. J Toxicol Sci. 2023;48:333–343.
Yang H, Zhang Y, Zhou R, et al. Antibiotics-induced depletion of rat microbiota induces changes in the expression of host drug-processing genes and pharmacokinetic behaviors of CYPs probe drugs. Drug Metab Dispos. 2023;51:509–520.
Togao M, Tajima S, Kurakawa T, et al. Normal variation of the gut microbiota affects hepatic cytochrome P450 activity in mice. Pharmacol Res Perspect. 2021;9:e00893.
Togao M, Kawakami K, Otsuka J, et al. Effects of gut microbiota on in vivo metabolism and tissue accumulation of cytochrome P450 3A metabolized drug: midazolam. Biopharm Drug Dispos. 2020;41:275–282.
Toda T, Saito N, Ikarashi N, et al. Intestinal flora induces the expression of Cyp3a in the mouse liver. Xenobiotica. 2009;39:323–334.
Kuno T, Hirayama-Kurogi M, Ito S, et al. Effect of intestinal flora on protein expression of drug-metabolizing enzymes and transporters in the Liver and Kidney of Germ-Free and Antibiotics-Treated Mice. Mol Pharm. 2016;13:2691–2701.
Selwyn FP, Cui JY, Klaassen CD. RNA-Seq Quantification of Hepatic Drug Processing Genes in Germ-Free Mice. Drug Metab Dispos. 2015;43:1572–1580.
Degraeve AL, Haufroid V, Loriot A, et al. Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1. Microbiome. 2023;11:138.
Chan S, Cao C, Pascoe EM, et al. Patient-reported gastrointestinal symptoms and the association with quality of life following kidney transplantation. Kidney Inter Rep. 2021;6:138–145.
Bunnapradist S, Neri L, Wong W, et al. Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality. Am J Kidney Dis. 2008;51:478–486.
Nakamura A, Amada N, Haga I, et al. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. Transplant Proc. 2014;46:592–594.
Staatz CE, Taylor PJ, Lynch SV, et al. A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation. Liver Transpl. 2004;10:506–512.
Tan ST, Yoong BK. Effect of diarrhoea on tacrolimus trough level in a post liver transplant patient. Med J Malaysia. 2020;75:734–735.
Matsui A, Arakawa Y, Momoya T, et al. Apparently increased trough levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation. Acta Paediatr Jpn. 1996;38:699–701.
Berengue JI, López-Espinosa JA, Ortega-López J, et al. Two- to three-fold increase in blood tacrolimus (FK506) levels during diarrhea in liver-transplanted children. Clin Transplant. 2003;17:249–253.
Zylber-Katz E, Granot E. Abrupt increase of tacrolimus blood levels during an episode of Shigella infection in a child after liver transplantation. Ther Drug Monit. 2001;23:647–649.
Eades SK, Boineau FG, Christensen ML. Increased tacrolimus levels in a pediatric renal transplant patient attributed to chronic diarrhea. Pediatr Transplant. 2000;4:63–66.
Maes BD, Lemahieu W, Kuypers D, et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant. 2002;2:989–992.
Lemahieu W, Maes B, Verbeke K, et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant. 2005;5:1383–1391.
Sato K, Amada N, Sato T, et al. Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients. Clin Transplant. 2004;18:585–590.
Chung The H, Le SNH. Dynamic of the human gut microbiome under infectious diarrhea. Curr Opin Microbiol. 2022;66:79–85.
Bhagat V, Pandit RA, Ambapurkar S, et al. Drug interactions between antimicrobial and immunosuppressive agents in solid organ transplant recipients. Indian J Crit Care Med. 2021;25:67–76.
Zheng Y, Masand A, Wagner M, et al. Identification of antibiotic administration as a potentially novel factor associated with tacrolimus trough variability in kidney transplant recipients: a preliminary study. Transplant Direct. 2019;5:e485.
Federico S, Carrano R, Capone D, et al. Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation. Clin Pharmacokinet. 2006;45:169–175.
Page RL, Klem PM, Rogers C. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. Ann Pharmacother. 2005;39:1109–1113.
Early CR, Park JM, Dorsch MP, et al. Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for Clostridium difficile. Transpl Infect Dis. 2016;18:714–720.
Shullo MA, Schonder K, Teuteberg JJ. Elevated tacrolimus levels associated with intravenous azithromycin and ceftriaxone: a case report. Transplant Proc. 2010;42:1870–1872.
Isoda K, Takeuchi T, Kotani T, et al. The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases. Intern Med. 2014;53:1413–1418.
Rančić N, Dragojević-Simić V, Vavić N, et al. Tacrolimus concentration/dose ratio as a therapeutic drug monitoring strategy: the influence of gender and comedication. Vojnosanit Pregl. 2015;72:813–822.
Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37:201–211.
Miura M, Inoue K, Kagaya H, et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos. 2007;28:167–175.
Swarte JC, Douwes RM, Hu S, et al. Characteristics and dysbiosis of the gut microbiome in renal transplant recipients. J Clin Med. 2020;9:386.
Bruno G, Zaccari P, Rocco G, et al. Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified. World J Gastroenterol. 2019;25:2706–2719.
Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–748.
Takagi T, Naito Y, Inoue R, et al. The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case-control study. J Clin Biochem Nutr. 2018;62:100–105.
Tsuda A, Suda W, Morita H, et al. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol. 2015;6:e89.
Beak JA, Park MJ, Kim SY, et al. FK506 and Lactobacillus acidophilus ameliorate acute graft-versus-host disease by modulating the T helper 17/regulatory T-cell balance. J Transl Med. 2022;20:104.
Kim DS, Park Y, Choi JW, et al. Lactobacillus acidophilus supplementation exerts a synergistic effect on tacrolimus efficacy by modulating Th17/Treg balance in lupus-prone mice via the SIGNR3 pathway. Front Immunol. 2021;12:696074.
Lv W, Zhang D, He T, et al. Combination of Lactobacillus plantarum improves the effects of tacrolimus on colitis in a mouse model. Front Cell Infect Microbiol. 2023;13:1130820.
Jiao W, Zhang Z, Xu Y, et al. Butyric acid normalizes hyperglycemia caused by the tacrolimus-induced gut microbiota. Am J Transplant. 2020;20:2413–2424.
Toral M, Romero M, Rodríguez-Nogales A, et al. Lactobacillus fermentum improves tacrolimus-induced hypertension by restoring vascular redox state and improving eNOS coupling. Mol Nutr Food Res. 2018;62:e1800033.
Lopez-Siles M, Duncan SH, Garcia-Gil LJ, et al. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. ISME J. 2017;11:841–852.
Leylabadlo HE, Ghotaslou R, Feizabadi MM, et al. The critical role of Faecalibacterium prausnitzii in human health: an overview. Microb Pathog. 2020;149:104344.
Ferreira-Halder CV, Faria AV de S, Andrade SS. Action and function of Faecalibacterium prausnitzii in health and disease. Best Pract Res Clin Gastroenterol. 2017;31:643–648.
He X, Zhao S, Li Y. Faecalibacterium prausnitzii: a next-generation probiotic in gut disease improvement. Can J Infect Dis Med Microbiol. 2021;2021:1–10.
Khan MT, Dwibedi C, Sundh D, et al. Synergy and oxygen adaptation for development of next-generation probiotics. Nature. 2023;620:381–385.
Dalal P, Grafals M, Chhabra D, et al. Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection. Ther Clin Risk Manag. 2009;5:139–149.
Zhang D, Chow DSL. Clinical pharmacokinetics of mycophenolic acid in hematopoietic stem cell transplantation recipients. Eur J Drug Metab Pharmacokinet. 2017;42:183–189.
Iida M, Fukuda T, Uchida N, et al. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs-host disease in adult patients in Japan. Clin Transplant. 2014;28:980–989.
Bergan S, Brunet M, Hesselink DA, et al. Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology. Ther Drug Monit. 2021;43:150–200.
Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429–455.
Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos. 2004;32:775–778.
Hesselink DA, van Hest RM, Mathot RAA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987–994.
Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther. 2004;309:1029–1035.
Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc. 1996;28:925–929.
de Winter BCM, Mathot RAA, Sombogaard F, et al. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. Ther Drug Monit. 2010;32:606–614.
Khan MH, Onyeaghala GC, Rashidi A, et al. Fecal β-glucuronidase activity differs between hematopoietic cell and kidney transplantation and a possible mechanism for disparate dose requirements. Gut Microbes. 2022;14:2108279.
Javdan B, Lopez JG, Chankhamjon P, et al. Personalized mapping of drug metabolism by the human gut microbiome. Cell. 2020;181:1661–1679.e22.
Simpson JB, Sekela JJ, Graboski AL, et al. Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate. Gut Microbes. 2022;14:2107289.
Naderer OJ, Dupuis RE, Heinzen EL, et al. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol. 2005;45:219–226.
Borrows R, Chusney G, James A, et al. Determinants of mycophenolic acid levels after renal transplantation. Ther Drug Monit. 2005;27:442–450.
Ratna P, Mathew BS, Annapandian VM, et al. Pharmacokinetic drug interaction of mycophenolate with co-amoxiclav in renal transplant patients. Transplantation. 2011;91:e36–e38.
Borrows R, Chusney G, Loucaidou M, et al. The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation. Ther Drug Monit. 2007;29:122–126.
Goutelle S, Mialou V, Gouraud A, et al. Probable drug interaction between intravenous ciprofloxacin and mycophenolate mofetil in a bone marrow transplant recipient. Pharmacotherapy. 2011;31:114–114.
Dukaew N, Thongkumkoon P, Sirikaew N, et al. Gut Microbiota-mediated pharmacokinetic drug-drug interactions between mycophenolic acid and trimethoprim-sulfamethoxazole in humans. Pharmaceutics. 2023;15:1734.
Simoons M, Naipal KAT, de Jong H, et al. Oral antibiotics lower mycophenolate mofetil drug exposure, possibly by interfering with the enterohepatic recirculation: a case series. Pharmacol Res Perspect. 2023;11:e01103.
Schmidt LE, Rasmussen A, Nørrelykke MR, et al. The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. Liver Transpl. 2001;7:739–742.
Tian JX, Miao WJ, Yan HH, et al. Impact of carbapenem antibiotics on mycophenolate mofetil in hematopoietic stem cell transplant patients with interruption of the enterohepatic recycling: a retrospective study. Ann Transl Med. 2023;11:82.
Rashidi A, Kaiser T, Holtan SG, et al. Levaquin gets a pass. Biol Blood Marrow Transplant. 2020;26:778–781.
Kodawara T, Masuda S, Yano Y, et al. Inhibitory effect of ciprofloxacin on β-glucuronidase-mediated deconjugation of mycophenolic acid glucuronide. Biopharm Drug Dispos. 2014;35:275–283.
Gabardi S, Olyaei A. Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors. Ann Pharmacother. 2012;46:1054–1064.
Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit. 2008;30:46–51.
Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant. 2009;28:605–611.
Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc. 2010;42:4243–4246.
Sakuludomkan W, Na Takuathung M, Dukaew N, et al. Drug-drug interactions between mycophenolic acid and proton pump inhibitors: a systematic review and meta-analysis. Ther Drug Monit. 2022;44:384–390.
Boonpheng B, Thongprayoon C, Bathini T, et al. Proton pump inhibitors and adverse effects in kidney transplant recipients: a meta-analysis. World J Transplant. 2019;9:35–47.
Sunderland A, Russ G, Sallustio B, et al. Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. Nephrol Dial Transplant. 2020;35:1060–1070.
Kofler S, Wolf C, Shvets N, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant. 2011;30:565–571.
Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34:771–785.
Davies NM, Grinyo J, Heading R, et al. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant. 2007;22:2440–2448.
Angarone M, Snydman DR; AST ID Community of Practice. Diagnosis and management of diarrhea in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13550.
Zhang LT, Westblade LF, Iqbal F, et al. Gut microbiota profiles and fecal beta-glucuronidase activity in kidney transplant recipients with and without post-transplant diarrhea. Clin Transplant. 2021;35:e14260.
Lee JR, Magruder M, Zhang L, et al. Gut microbiota dysbiosis and diarrhea in kidney transplant recipients. Am J Transplant. 2019;19:488–500.
Taylor MR, Flannigan KL, Rahim H, et al. Vancomycin relieves mycophenolate mofetil-induced gastrointestinal toxicity by eliminating gut bacterial β-glucuronidase activity. Sci Adv. 2019;5:eaax2358.
Braghieri L, Jennings DL, Bohn B, et al. Temporal shifts in safety and efficacy profile of mycophenolate mofetil 2 g versus 3 g daily early after heart transplantation. Pharmacotherapy. 2022;42:697–706.
Salvadori M, Holzer H, de Mattos A, et al.; ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4:231–236.
Salvadori M, Holzer H, Civati G, et al.; ERL B301 Study Group. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients. Clin Nephrol. 2006;66:112–119.
Pape L, Ahlenstiel T, Kreuzer M, et al. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children. Pediatr Transplant. 2008;12:640–642.
Ortega F, Sánchez-Fructuoso A, Cruzado JM, et al.; MYVIDA Study Group. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Transplantation. 2011;92:426–432.
Budde K, Curtis J, Knoll G, et al.; ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004;4:237–243.
Kobashigawa JA, Renlund DG, Gerosa G, et al.; ERL2401 Heart Study Investigators. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant. 2006;25:935–941.
Ciancio G, Gaynor JJ, Zarak A, et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. Transplantation. 2011;91:1198–1205.
Gozdowska J, Urbanowicz A, Baczkowska T, et al. Safety and tolerance of sodium mycophenolate in patients after renal transplantation—an observational study. Transplant Proc. 2009;41:3016–3018.
Gardiner KM, Tett SE, Staatz CE. Is conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium justifiable for gastrointestinal quality of life? Drugs R D. 2018;18:271–282.
Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012;52:1265–1272.
Budde K, Bauer S, Hambach P, et al. Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. Am J Transplant. 2007;7:888–898.
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007;46:13–58.
Vuik F, Dicksved J, Lam S, et al. Composition of the mucosa-associated microbiota along the entire gastrointestinal tract of human individuals. United Eur Gastroenterol J. 2019;7:897–907.
Shipkova M, Armstrong VW, Oellerich M, et al. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit. 2003;25:1–16.
LoGuidice A, Wallace BD, Bendel L, et al. Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther. 2012;341:447–454.
Jardou M, Provost Q, Brossier C, et al. Alteration of the gut microbiome in mycophenolate-induced enteropathy: impacts on the profile of short-chain fatty acids in a mouse model. BMC Pharmacol Toxicol. 2021;22:66.
Candeliere F, Raimondi S, Ranieri R, et al. β-Glucuronidase pattern predicted from gut metagenomes indicates potentially diversified pharmacomicrobiomics. Front Microbiol. 2022;13:826994.
Zhou J, Zhang R, Guo P, et al. Effects of intestinal microbiota on pharmacokinetics of cyclosporine A in rats. Front Microbiol. 2022;13:1032290.
Yadav V, Gaisford S, Merchant HA, et al. Colonic bacterial metabolism of corticosteroids. Int J Pharm. 2013;457:268–274.
Ma L, Zhang L, Zhuang Y, et al. Lactobacillus improves the effects of prednisone on autoimmune hepatitis via gut microbiota-mediated follicular helper T cells. Cell Commun Signal. 2022;20:83.
Arrabi L, Jan A, Hosing C, et al. Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation. Eur J Haematol. 2021;107:634–641.
Zhao DQ, Li SW, Sun QQ. Sirolimus-based immunosuppressive regimens in renal transplantation: a systemic review. Transplant Proc. 2016;48:3–9.
Han Y, Wu L, Ling Q, et al. Intestinal dysbiosis correlates with sirolimus-induced metabolic disorders in mice. Transplantation. 2021;105:1017–1029.
Klünemann M, Andrejev S, Blasche S, et al. Bioaccumulation of therapeutic drugs by human gut bacteria. Nature. 2021;597:533–538.
Guthrie L, Wolfson S, Kelly L. The human gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs. Elife. 2019;8:e42866.